CC-5013 MM 0017: a multicenter, randomized, parallel-group, double-blind, placebo-controlled study of CC-5013 plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002985:Clinical Protocols; D003907:Dexamethasone / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D018579:Patient Selection; D010919:Placebos; D016879:Salvage Therapy / Q000379:methods*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D010919:Placebos; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide